WC
BLUE

Wexford Capital’s bluebird bio BLUE Stock Holding History

Wexford Capital’s Portfolio BLUE Stock Details BLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,623
Closed -$1.47M – 216
2020
Q4 		$1.47M Buy
+2,623
New +$1.66M 0.23% 89
2020
Q3 		– Sell
-733
Closed -$580K – 187
2020
Q2 		$580K Buy
+733
New +$553K 0.15% 80
2017
Q3 		– Sell
-255
Closed -$347K – 152
2017
Q2 		$347K Buy
+255
New +$308K 0.03% 140

Other funds holding BLUE

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wexford Capital's BLUE Position: Q1 2021 in Review

Wexford Capital sold out of bluebird bio (BLUE) in Q1 2021, closing a stake of 2,623 shares — an estimated $1.47M sold.

Wexford Capital first reported a position in BLUE in Q2 2017 and held it in 3 quarters. The position peaked at $1.47M in Q4 2020. 229 funds tracked by Wall St. Rank hold BLUE as of Q1 2021.

  • Wexford Capital reported no remaining bluebird bio position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 2,623 bluebird bio shares in Q1 2021, an estimated $1.47M.
  • Wexford Capital first reported a position in bluebird bio in Q2 2017 and held it in 3 quarters.
  • Wexford Capital's bluebird bio position peaked at $1.47M in Q4 2020.
  • 229 funds tracked by Wall St. Rank held bluebird bio as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.